Display options
Cite
Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201-14doi: 10.2147/TACG.S48605.
Pischik, E., & Kauppinen, R. (2015). An update of clinical management of acute intermittent porphyria. The application of clinical genetics, 8201-14. https://doi.org/10.2147/TACG.S48605
Pischik, Elena, and Kauppinen, Raili. "An update of clinical management of acute intermittent porphyria." The application of clinical genetics vol. 8 (2015): 201-14. doi: https://doi.org/10.2147/TACG.S48605
Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015 Sep 01;8:201-14. doi: 10.2147/TACG.S48605. eCollection 2015. PMID: 26366103; PMCID: PMC4562648.
Copy Download .nbib Format: NLM
Share it on

Appl Clin Genet. 2015 Sep 01;8:201-14. doi: 10.2147/TACG.S48605. eCollection 2015.

An update of clinical management of acute intermittent porphyria.

The application of clinical genetics

Elena Pischik, Raili Kauppinen

Affiliations

  1. Porphyria Research Unit, Division of Endocrinology, Department of Medicine, University Central Hospital of Helsinki, Helsinki, Finland ; Department of Neurology, Consultative and Diagnostic Centre with Polyclinics, St Petersburg, Russia.
  2. Porphyria Research Unit, Division of Endocrinology, Department of Medicine, University Central Hospital of Helsinki, Helsinki, Finland.

PMID: 26366103 PMCID: PMC4562648 DOI: 10.2147/TACG.S48605

Abstract

Acute intermittent porphyria (AIP) is due to a deficiency of the third enzyme, the hydroxymethylbilane synthase, in heme biosynthesis. It manifests with occasional neuropsychiatric crises associated with overproduction of porphyrin precursors, aminolevulinic acid and porphobilinogen. The clinical criteria of an acute attack include the paroxysmal nature and various combinations of symptoms, such as abdominal pain, autonomic dysfunction, hyponatremia, muscle weakness, or mental symptoms, in the absence of other obvious causes. Intensive abdominal pain without peritoneal signs, acute peripheral neuropathy, and encephalopathy usually with seizures or psychosis are the key symptoms indicating possible acute porphyria. More than fivefold elevation of urinary porphobilinogen excretion together with typical symptoms of an acute attack is sufficient to start a treatment. Currently, the prognosis of the patients with AIP is good, but physicians should be aware of a potentially fatal outcome of the disease. Mutation screening and identification of type of acute porphyria can be done at the quiescent phase of the disease. The management of patients with AIP include following strategies: A, during an acute attack: 1) treatment with heme preparations, if an acute attack is severe or moderate; 2) symptomatic treatment of autonomic dysfunctions, polyneuropathy and encephalopathy; 3) exclusion of precipitating factors; and 4) adequate nutrition and fluid therapy. B, during remission: 1) exclusion of precipitating factors (education of patients and family doctors), 2) information about on-line drug lists, and 3) mutation screening for family members and education about precipitating factors in mutation-positive family members. C, management of patients with recurrent attacks: 1) evaluation of the lifestyle, 2) evaluation of hormonal therapy in women, 3) prophylactic heme therapy, and 4) liver transplantation in patients with severe recurrent attacks. D, follow-up of the AIP patients for long-term complications: chronic hypertension, chronic kidney insufficiency, chronic pain syndrome, and hepatocellular carcinoma.

Keywords: acute intermittent porphyria; heme; neuropathy; porphyria; treatment

References

  1. Mol Cell Biochem. 2003 Aug;250(1-2):65-71 - PubMed
  2. Mol Ther. 2010 Jan;18(1):17-22 - PubMed
  3. J Inherit Metab Dis. 2013 Nov;36(6):1063-71 - PubMed
  4. Am J Hum Genet. 1997 Jun;60(6):1373-83 - PubMed
  5. J Intern Med. 1994 Aug;236(2):169-75 - PubMed
  6. Cell Mol Biol (Noisy-le-grand). 2009 Feb 16;55(1):72-83 - PubMed
  7. Q J Med. 1959 Apr;28(110):183-209 - PubMed
  8. Ann Clin Res. 1986;18(4):195-8 - PubMed
  9. Ann Intern Med. 2011 Apr 19;154(8):571-2 - PubMed
  10. Proc Natl Acad Sci U S A. 2014 May 27;111(21):7777-82 - PubMed
  11. Clin Nephrol. 2008 May;69(5):339-46 - PubMed
  12. Scand J Clin Lab Invest. 2009;69(5):612-8 - PubMed
  13. Ann Clin Biochem. 2013 May;50(Pt 3):217-23 - PubMed
  14. J Clin Pathol. 2001 Jul;54(7):500-7 - PubMed
  15. Transplantation. 2010 Jan 15;89(1):61-8 - PubMed
  16. Hum Gene Ther. 2013 Dec;24(12):1007-17 - PubMed
  17. Am J Med Genet. 1996 Nov 11;65(4):269-73 - PubMed
  18. J Formos Med Assoc. 2013 Sep;112(9):578-9 - PubMed
  19. Medicine (Baltimore). 1992 Jan;71(1):1-13 - PubMed
  20. Mol Ther. 2004 Aug;10(2):337-43 - PubMed
  21. Ann Intern Med. 2006 Apr 4;144(7):537-8 - PubMed
  22. J Biol Chem. 2002 Sep 20;277(38):34717-26 - PubMed
  23. Hum Gene Ther Clin Dev. 2014 Jun;25(2):61-3 - PubMed
  24. J Intern Med. 2011 May;269(5):538-45 - PubMed
  25. Scand J Clin Lab Invest. 2000 Nov;60(7):541-59 - PubMed
  26. Acta Obstet Gynecol Scand. 1997 May;76(5):484-5 - PubMed
  27. Medicine (Baltimore). 1970 Jan;49(1):1-16 - PubMed
  28. Hosp Med. 2001 Jul;62(7):422-5 - PubMed
  29. Hum Genet. 1999 Jun;104(6):505-10 - PubMed
  30. Neuroradiology. 1999 Nov;41(11):835-9 - PubMed
  31. Cell. 2005 Aug 26;122(4):505-15 - PubMed
  32. Transpl Int. 2010 Jun;23(6):e18-21 - PubMed
  33. Liver Transpl. 2012 Feb;18(2):195-200 - PubMed
  34. Mol Genet Metab. 2004 May;82(1):20-6 - PubMed
  35. J Clin Pharmacol. 2003 Oct;43(10 ):1158-60 - PubMed
  36. Eur J Neurol. 2006 Jun;13(6):668-9 - PubMed
  37. Am J Med. 2006 Jan;119(1):88-90 - PubMed
  38. Am J Med. 1988 Oct;85(4):538-40 - PubMed
  39. Clin Biochem. 2000 Aug;33(6):465-73 - PubMed
  40. Nephrol Dial Transplant. 1992;7(10):986-90 - PubMed
  41. Mol Cell Biochem. 1981 Aug 11;38 Spec No(Pt 1):49-58 - PubMed
  42. Acta Obstet Gynecol Scand. 2010;89(1):95-100 - PubMed
  43. J Neurol. 2008 Jul;255(7):974-9 - PubMed
  44. Acta Med Scand. 1984;215(3):271-4 - PubMed
  45. J Am Soc Nephrol. 1992 Mar;2(9):1445-50 - PubMed
  46. Clin Genet. 2008 Oct;74(4):396-8 - PubMed
  47. Lancet. 2005 Jan 15-21;365(9455):241-52 - PubMed
  48. J Inherit Metab Dis. 2010 Oct;33(5):591-6 - PubMed
  49. Endocr Rev. 2010 Aug;31(4):544-77 - PubMed
  50. Horm Metab Res. 1995 Aug;27(8):379-83 - PubMed
  51. Hum Genet. 2000 Sep;107(3):243-8 - PubMed
  52. Arch Intern Med. 1990 Jul;150(7):1469-74 - PubMed
  53. Br J Cancer. 1988 Jan;57(1):117-20 - PubMed
  54. Expert Rev Mol Diagn. 2004 Mar;4(2):243-9 - PubMed
  55. Arch Neurol. 2004 Nov;61(11):1764-70 - PubMed
  56. Trends Biotechnol. 2004 Jun;22(6):304-10 - PubMed
  57. Proc Natl Acad Sci U S A. 1989 Jan;86(2):661-4 - PubMed
  58. Clin Chem. 2002 Nov;48(11):1891-900 - PubMed
  59. J Intern Med. 1996 Oct;240(4):195-201 - PubMed
  60. J Neurosci. 2004 Sep 1;24(35):7604-13 - PubMed
  61. Am J Med. 2014 Dec;127(12):1233-41 - PubMed
  62. Am J Med. 2006 Sep;119(9):801.e19-24 - PubMed
  63. Liver Transpl. 2008 Oct;14(10):1428-36 - PubMed
  64. Q J Med. 1990 Apr;75(276):355-63 - PubMed
  65. Scand J Clin Lab Invest. 2002;62(2):105-13 - PubMed
  66. Am J Med. 2001 Feb 15;110(3):240 - PubMed
  67. Acta Obstet Gynecol Scand. 2012 Dec;91(12):1445-52 - PubMed
  68. Clin Pharmacokinet. 2007;46(4):335-49 - PubMed
  69. J Inherit Metab Dis. 2013 Sep;36(5):849-57 - PubMed
  70. J Lab Clin Med. 1976 Feb;87(2):362-70 - PubMed
  71. J Cardiovasc Med (Hagerstown). 2015 May;16(5):372-82 - PubMed
  72. Transpl Int. 2007 Jul;20(7):591-9 - PubMed
  73. Cell Mol Biol (Noisy-le-grand). 2009 Feb 16;55(1):66-71 - PubMed
  74. Hepatology. 2014 Sep;60(3):1082-9 - PubMed
  75. Environ Health Perspect. 1997 Feb;105 Suppl 1:37-53 - PubMed
  76. Eur J Intern Med. 2009 Mar;20(2):201-7 - PubMed
  77. Semin Liver Dis. 1998;18(1):43-52 - PubMed
  78. J Clin Endocrinol Metab. 1970 Mar;30(3):330-5 - PubMed
  79. Medicine (Baltimore). 2005 Jan;84(1):48-60 - PubMed
  80. Eur J Endocrinol. 1999 Jul;141(1):50-4 - PubMed
  81. Eur J Hum Genet. 2002 Oct;10(10):649-57 - PubMed
  82. J Intern Med. 2003 Aug;254(2):176-83 - PubMed
  83. Ann Intern Med. 2005 Mar 15;142(6):439-50 - PubMed
  84. Acta Med Scand. 1976;200(3):171-8 - PubMed
  85. Medicine (Baltimore). 2005 Jan;84(1):35-47 - PubMed
  86. Q J Med. 1969 Jul;38(151):307-33 - PubMed
  87. J Neurol. 2004 Dec;251(12):1538-41 - PubMed
  88. N Engl J Med. 1990 Feb 1;322(5):315-7 - PubMed
  89. Semin Liver Dis. 1998;18(1):57-65 - PubMed
  90. Lancet. 1989 Jun 10;1(8650):1295-7 - PubMed
  91. Arch Intern Med. 1993 Sep 13;153(17):2004-8 - PubMed
  92. J Clin Pathol. 2012 Nov;65(11):976-80 - PubMed
  93. Mol Med. 2003 Sep-Dec;9(9-12):193-9 - PubMed
  94. Metabolism. 1964 May;13:396-406 - PubMed
  95. Liver Int. 2015 Jan;35 Suppl 1:129-38 - PubMed

Publication Types